




university of
 groningen



9/12/2021 | 1

BIOMIMETIC NANOPARTICLES FOR BIOMEDICAL APPLICATIONS

HÉLDER A. SANTOS

Full Professor in Biomedical Engineering
Head, Department of Biomedical Engineering
University Medical Center Groningen

Scientific Director, Health Technology Research and Innovation Cluster (HTRIC)

&

Head, Nanomedicine and Biomedical Engineering Lab
Faculty of Pharmacy, University of Helsinki

&

Visiting Professorships, University of Tartu and
Shanghai Jiao Tong University School of Medicine



h.a.santos@umcg.nl

Dr. Santos' Lab | YouTube
@Santos_Lab15 | Twitter




CRS 2022 Annual Meeting & Expo

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada

Advanced Delivery Science



university of
 groningen



umcg



DISSOLVING MICRONEEDLES TO ATTENUATE INFLAMMATION

Tomás Bauleth-Ramos^{1,2,*}, Mohammad-Ali Shahbazi^{1,3}, Christos Tapeinos¹, Raquel Bártolo¹, Maria Lobito⁴, João Pedro Martins⁵, Ermei Makilä^{1,3}, Jarmo Salonen³, Helder A. Santos^{1,2}

¹Drug Research program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
²Department of Biomedical Engineering and W.J. Kolff Institute for Biomedical Engineering and Materials Science, University Medical Center Groningen/University of Groningen, 3000 Al, Groningen, The Netherlands
³Laboratory of Industrial Physics, Department of Physics, University of Turku, Finland

SANTO LAB

*e-mail: tomas.bauleth-ramos@helsinki.fi


INTRODUCTION

Inflammation is a crucial healing process for many diseases, including cardiovascular diseases such as myocardial infarction (MI). However, excessive inflammatory response can be detrimental effect, exacerbating the consequences and leading to a poor clinical outcome.¹ Therefore, there is the need to find ways to easily attenuate inflammation. Microneedles (MNs) are remarkable drug delivery systems for immunomodulation due to their ability to deliver transdermally a broad array of molecules in a painless and minimally invasive manner. Moreover, nanoparticles (NPs) due to their multiple advantages, such as targeting capacity, controlled delivery, and immunomodulatory properties, are also promising for immunotherapy.²⁻⁵ Considering this, we hypothesized that by delivering D-Mannose modified NPs loaded with interleukin-4 (IL-4) through dissolving MNs, we are able to modulate from M₁ (pro-inflammatory) to a M₂ (anti-inflammatory) state, attenuating inflammation.

AIMS

- 1 To prepare fast dissolving MNs with intrinsic immunomodulatory properties and ability to transdermal deliver NPs and cytokines.
- 2 Physicochemical characterization of the developed NPs and MNs independently and combined.
- 3 *In vitro* evaluation of the cytocompatibility of the developed system, cellular uptake and macrophage polarization.

RESULTS



Poster
#389



TRAGACANTH-BASED INJECTABLE HYDROGEL LOADED WITH SPERMINE-ACETALATED DEXTRAN NANOPARTICLES FOR TARGETED MIRNA DELIVERY


Raquel Bártolo¹, Tomás Bauleth-Ramos^{1,2}, Giulia Torrieri², Shiqi Wang³, Karla Gomez³, Mohammad-Ali Shahbazi¹, Peter v. d. Meer³, Helder A. Santos^{1,2}

¹Department of Biomedical Engineering and W.J. Kolff Institute for Biomedical Engineering and Materials Science, University Medical Center Groningen/University of Groningen, ²Drug Research program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland, ³Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands

1. Introduction and Objectives

Myocardial infarction (MI) is a life-threatening condition characterized by irreversible cell death [1]. During the past decades, several therapeutic strategies have held the promise of restoring the full functionality of a damaged heart. However, MI approved therapies, to date, only ameliorate the state of care of these patients [2]. Therefore, new therapeutic approaches need to be explored.

Herein, we have developed a nanoparticle (NP) composite injectable hydrogel for MI treatment. This system consists of a tragacanth-based injectable hydrogel (Scheme 1), containing cytokines and spermine-acetalated dextran-based (AcDxSp) [3] functional NPs loaded with miRNA. We hypothesized that this system can modulate the immunoenvironment present in the heart after MI and induce cardiac fibroblasts differentiation to myofibroblasts, while inducing a cardioprotective effect.



2. Methods and Results

- NPs fabrication by double emulsion technique
- NPs PEGylation and further conjugation with ANP through EDC/NHS reaction
- Metal coordination: Gel preparation by vigorous vortexing



3. Conclusions and Future work

- We successfully produced and modified NPs with PEG and ANP.
- The produced NPs were loaded into the injectable Gel for NPs' control release.
- The combined system showed biocompatibility in the tested conditions.
- In the future, studies for immunomodulation and cell differentiation *in vitro* and *in vivo* will be conducted.

Figure 2: NPs-Gel composite characterization. (A) Hydrodynamic diameter, PDI, and z-potential of AcDxSp, AcDxSp-PEG, and AcDxSp-PEG-ANP NPs. (B) Evaluation of the impact of cell medium on the colloidal stability of AcDxSp, AcDxSp-PEG, and AcDxSp-PEG-ANP NPs upon incubation for 120 min at 37 °C. (C) Gel injectability tests with different needle gauges. (D) Self-healing properties of the Gel fabricated with different dyes. (E) Cellular biocompatibility of embryonic STEAM cell derived cardiomyocytes measured by Alamar Blue upon 24h incubation with NPs and Gel. The results are represented as the mean ± s.d. (n = 3-6).

Acknowledgments: Financial support from the UMCG Research Funds, the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 801718 and the Academy of Finland decision No 331106 is acknowledged.

References: [1] K. Thygesen et al., Circulation, 2018, 138 (20), 4618-4655; [2] K. M. Eggers, T. Jernberg, and B. Lindahl, Sci. Rep., 2021, 11 (1), 1-1; [3] G. Torrieri et al., Adv. Funct. Mater., 2022, 32 (5), 2109032.

2


Poster
#355



CRS 2022 Annual Meeting & Expo

Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada



CHALLENGES IN CANCER AND CVDS TREATMENTS

LIMITATIONS OF CURRENT TREATMENT

Surgery:

1. Cannot treat most of metastatic cancer, pancreas, as well as some brain tumors;
2. Associated with potential risks.


Radiotherapy:

1. Limited curative effect;
2. Body damage and development of other cancers


Chemotherapy:

1. Increase in the development cost;
2. Mortality rates increase continuously

Restore perfusion
Decrease blood pressure, cardiac overload
Aid blood systemic distribution
Prevent arrhythmias



Stent
Angioplasty




Ventricular assist devices




Pharmacological therapy

- ACE inhibitors
- Ang-II receptor blockers
- β -blockers
- Mineralocorticoid-receptor antagonists
- Diuretics
- Digoxin
- Thrombolytic therapy



Pacemaker




Heart transplant

New treatment solutions are urgently needed!



university of
groningen



umcg

9/12/2021 | 4

PNAS

Proceedings of the
National Academy of Sciences
of the United States of America

Keyword, Author, or

Home

Articles

Front Matter

News

Podcasts

Authors

NEW RESEARCH IN

Physical Sciences

Social Sciences

Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression

Hongbo Zhang, Wenguo Cui, Xiangmeng Qu, Huayin Wu, Liangliang Qu, Xu Zhang, Ermei Mäkilä, Jarno Salonen, Yueqi Zhu, Zhou Yang, Dong Chen, Hélder A. Santos, Mingtan Hai, and David A. Weitz

PNAS April 16, 2019 116 (16) 7744–7749; first published March 29, 2019 <https://doi.org/10.1073/pnas.1817251116>
Add to Cart (\$10)

Edited by Tobin J. Marks, Northwestern University, Evanston, IL, and approved March 6, 2019 (received for review October 10, 2018)



ARTICLE

<https://doi.org/10.1038/s41467-022-28787-7>

OPEN

High drug-loaded microspheres enabled by controlled in-droplet precipitation promote functional recovery after spinal cord injury

Wei Li^{1,7}, Jian Chen^{2,7}, Shujie Zhao², Tianhe Huang³, Huiyan Ying¹, Claudia Trujillo¹, Giuseppina Molinaro¹, Zheng Zhou², Tao Jiang², Wei Liu², Linwei Li², Yuancheng Bai³, Peng Quan^{1,4}, Yaping Ding¹, Jouni Hirvonen¹, Guoyong Yin^{2,8}, Hélder A. Santos^{1,5,6,8}, Jin Fan^{2,8} & Dongfei Liu^{3,1,5,8}



Microfluidics technology




CRS 2022 Annual Meeting & Expo

Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada



university of
groningen






umcg

Zhang, Santos et al., *Cell Rep.* **2021**, 35, 109131; *Adv. Funct. Mater.* **2021**, 31, 2101262

9/12/2021 | 5

LIGHT-CONTROLLED NANOSYSTEM WITH SIZE FLEXIBILITY IMPROVES TARGETED RETENTION FOR TUMOR SUPPRESSION





Cell Reports

CellPress
OPEN ACCESS

Report

Multistage signal-interactive nanoparticles improve tumor targeting through efficient nanoparticle-cell communications

Feng Zhang,^{1,2,10} Yiran Zhang,^{2,10} Li Kong,^{3,4,10} Huanhuan Luo,² Yuezhou Zhang,⁵ Ermei Mäkilä,⁶ Jarno Salonen,⁶ Jouni T. Hirvonen,¹ Yueqi Zhu,⁷ Yingsheng Cheng,⁷ Lianfu Deng,² Hongbo Zhang,^{2,8,*} Alexander Kros,⁴ Wenguo Cui,^{2,*} and Helder A. Santos^{1,9,11,*}




CRS 2022 Annual Meeting & Expo




Advanced Delivery Science


July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada

Targeting entity
"GPS"






Drug nano-carrier






TRANSFORMABLE DRUG DELIVERY SYSTEMS






NANOPARTICLES IN MEDICINE





university of
 groningen



umcg

9/12/2021 | 9



CRS 2022 Annual Meeting & Expo


Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada





university of
 groningen




umcg


Liu, Santos *et al.*, Adv. Funct. Mater., 2022, 10.1002/adfm.202204666

9/12/2021 | 10

PROMOTING CARDIAC REPAIR VIA NANOPARTICLES WITH EXCLUSIVE TARGETING CAPABILITY TOWARD MYOCARDIAL REPERFUSION INJURY USING MICROFLUIDICS



β -glucan NPs loaded with NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome inhibitor (CY-09)





Thermal resistant microfluidics assisted NPs production




CRS 2022 Annual Meeting & Expo




Advanced Delivery Science


July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada








Enhanced cardiac targeting







**CY-09@CG showed better efficiency
in ameliorating long-term prognosis
after I/R cardiac injury**

Enhanced cardiac function






Polysaccharide-based viral mimicry nanocomplex with pH-responsive membrane destabilization and macrophage-targeting capability for gene silencing in inflammatory tissue






university of
 groningen




umcg

Gao, Santos *et al.*, under review

9/12/2021 | 15



Synthesis and characterization of β -glucan based membrane-active polymer (EEPG)



Preparation and characterization of polymeric NPs




CRS 2022 Annual Meeting & Expo

Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada




university of
 groningen




umcg

Gao, Santos *et al.*, under review

9/12/2021 | 16



In vitro performance of siRNA@CEEPG NPs




In vivo biological effects of siRNA@CEEPG NPs




CRS 2022 Annual Meeting & Expo


Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada



Functional evaluation of RNAi nanoformulation





- β -glucan-based NPs show precise and efficient targeting capability toward Dectin-1⁺ monocytes/macrophages, which are main pathogenesis mediators for cardiac ischemic/reperfusion (I/R) injury.
- β -glucan NPs loaded with NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome inhibitor (CY-09) show better efficiency in ameliorating myocardial injury and heart failure induced by surgically induced I/R.
- A virus-inspired poly (alkyl methacrylate-co-methacrylic acid) fragment with pH-responsive membrane destabilization properties conjugated on barley β -glucans (EEPG) endow the nanocomplex with endosomal escape capabilities.
- EEPG nanocomplex with efficient siRNA loading can achieve potent *in vivo* gene silencing in a selective subset of leukocytes due to the inherent affinity of EEPG towards an innate phagocytic receptor, Dectin-1.





ARTIFICIALLY CLOAKED VIRAL NANOVACCINE FOR CANCER IMMUNOTHERAPY



Nature Commun. **2019**, 10, 5747


ARTICLE

<https://doi.org/10.1038/s41467-019-13744-8>

OPEN

Artificially cloaked viral nanovaccine for cancer immunotherapy

Manlio Fusciello^{1,8}, Flavia Fontana^{2,8}, Siri Tähtinen¹, Cristian Capasso¹, Sara Feola¹, Beatriz Martins¹, Jacopo Chiaro¹, Karita Peltonen¹, Leena Ylösmäki¹, Erko Ylösmäki¹, Firas Hamdan¹, Otto K. Kari¹, Joseph Ndika³, Harri Alenius^{3,4}, Arto Urtti^{1,5}, Jouni T. Hirvonen², Hélder A. Santos^{2,6*} & Vincenzo Cerullo^{1,6,7*}



TUMOR EXOSOME-BASED NANOPARTICLES FOR TARGETED CANCER CHEMOTHERAPY




Nature Commun. **2019**, 10(1), 3838

Article | Open Access | Published: 23 August 2019

Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy



Tuying Yong, Xiaoqiong Zhang, Nana Bie, Hongbo Zhang, Xuting Zhang, Fuying Li, Abdul Hakeem, Jun Hu, Lu Gan[✉], Hélder A. Santos[✉] & Xiangliang Yang[✉]

Nature Communications **10**, Article number: 3838 (2019) | Download Citation[↓]








MULTIFUNCTIONAL NANOVACCINES BASED ON PHOTOTHERMAL AND IMMUNOSTIMULATORY NANOPARTICULATE CORES FOR IMMUNOTHERAPY OF SOLID TUMORS






Nanovaccine preparation and characterization







Nanovaccine *in vitro* and *in vivo* anticancer efficacy studies




Group 1: Control
Group 2: NIR + ICB
Group 3: NIR + vaccine
Group 4: Vaccine + ICB
Group 5: NIR + vaccine + ICB


(Anti-CTLA-4 antibody)






ENGINEERED NEUTROPHIL-DERIVED EXOSOME-LIKE VESICLES FOR TARGETED CANCER THERAPY






SPION-modified, N-Ex-like NVs deliver DOX to inhibit tumor growth






university of
 groningen



umcg

- ICB immunotherapy + CCM@(PSiNPs@Au) nanovaccine and photothermal therapy, eliminate solid tumors and suppress their metastasis.
- Due to inhibition of the antitumor immune responses and the reversion of their immunosuppressive microenvironments.



□ **Exosomes** from neutrophils (N-Ex) induced tumor cell apoptosis.

□ Decorated N-Ex achieved higher tumor-targeting therapeutic effect.

□ N-Ex with DOX-loaded improved inhibition of tumor cell proliferation and selectively accumulate at the tumor sites under an external magnetic field, preventing tumor growth and prolonging the survival rate in mice.



CRS 2022 Annual Meeting & Expo


Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada







university of
groningen



umcg

#Groningen @ UMCG

h.a.santos@umcg.nl



#Helsinki @ UH



Dr. Santos' Lab | YouTube
@Santos_Lab15 | Twitter



CRS 2022 Annual Meeting & Expo


Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada





university of
 groningen



umcg

9/12/2021 | 27

THANK YOU!



CRS 2022 Annual Meeting & Expo

Advanced Delivery Science

July 11 – 15, 2022 | Montreal Congress Center, Montreal Canada

